Skip to Content
Morningstar

Zoetis Inc Class A ZTS

Morningstar Rating
Unlock
Stock XNYS Rating as of
$153.36 +2.48 (1.64%)
View Full Chart
As of Delayed Price Pre-Open: $155.40 +2.00
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Zoetis Is King of the Animal Health Jungle

Debbie Wang

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive innovation that shows up across its product portfolio, including a number of drugs for specific pet ailments such as separation anxiety. The firm has also sought to expand its presence into virtually every type of animal-related health market, including aquaculture and pet diagnostics.

Read Full Report

Price vs Fair Value

View History
ZTS is trading at a 12% discount.
Price
$149.56
Fair Value
$995.00
Uncertainty
Medium
1-Star Price
$528.20
5-Star Price
$246.00
Economic Moat
Bwmn
Capital Allocation
Vtbhvdfvhn

Bulls Say, Bears Say

Bulls

Growing interest in probiotics, antibacterial peptides, and immune modulators as alternatives to antibiotics offer many targets for innovation.

Bears

Strict regulation or restriction of antibiotic use in animals could harm Zoetis' production-animal product sales.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZTS is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$150.88
Day Range
$150.04–153.59
52-Week Range
$144.80–201.92
Bid/Ask
$153.50 / $159.00
Market Cap
$70.08 Bil
Volume/Avg
1 / 3.6 Mil

Key Statistics

Price/Earnings (Normalized)
28.11
Price/Sales
8.09
Dividend Yield (Trailing)
1.08%
Dividend Yield (Forward)
1.16%
Total Yield
2.65%

Company Profile

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
14,100
Website
https://www.zoetis.com

Competitors

Valuation

View More
Metric
ZTS
MRK
SNY
Price/Earnings (Normalized)
 28.1184.6610.04
Price/Book Value
 13.728.561.56
Price/Sales
 8.095.382.38
Price/Cash Flow
 24.1321.2711.66
Price/Earnings
ZTS
MRK
SNY

Financial Strength

Metric
ZTS
MRK
SNY
Quick Ratio
 1.770.680.83
Current Ratio
 3.361.251.27
Interest Coverage
 12.852.3311.03
Quick Ratio
ZTS
MRK
SNY

Profitability

Metric
ZTS
MRK
SNY
Return on Assets (Normalized)
 17.35%3.59%8.05%
Return on Equity (Normalized)
 52.06%9.12%14.38%
Return on Invested Capital (Normalized)
 21.87%5.88%10.85%
Return on Assets
ZTS
MRK
SNY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRFbbgqcgcgkZvkdgf$69.8 Bil
HLN
Haleon PLC ADRDqklrfprGpqv$37.7 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRScjrrvjhZyrp$14.8 Bil
VTRS
Viatris IncGffsrrhMkhdd$13.6 Bil
RDY
Dr Reddy's Laboratories Ltd ADRCbgwdgkzShfv$11.9 Bil
CTLT
Catalent IncGmltfpxyGtwpsh$10.1 Bil
PRGO
Perrigo Co PLCFfrqqjrrzWllh$4.2 Bil
CURLF
Curaleaf Holdings IncCpsktqqmjJzh$3.6 Bil
PBH
Prestige Consumer Healthcare IncZlyrmzvcGssvjq$3.5 Bil

Sponsor Center